Indegene Limited has scheduled a series of one-on-one investor and analyst meetings for July 17, 2026. The engagements will take place in Mumbai, Maharashtra, involving five key financial institutions and mutual funds.

The company disclosed the schedule pursuant to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Officials from Indegene will meet the following entities in person:

• Karma Capital
• ICICI Prudential Mutual Fund
• SBI Mutual Fund
• Enam Holdings
• Quant Mutual Fund

Meeting Details

All sessions are designated as individual meetings. The schedule is subject to change if necessary. Indegene stated that no unpublished price-sensitive information will be shared during these interactions.

The full details of the investor engagement are available on the company’s website.

BPC Genesis Fund I SPV Limited and its Person Acting in Concert (PAC), BPC Genesis Fund I-A SPV Limited, have completely exited their positions in Indegene Ltd by selling a combined total of 21,052,478 equity shares on August 6, 2026. The coordinated open market sales on the National Stock Exchange of India Limited (NSE) reduced the group’s aggregate holding from 8.743% of the total voting capital to zero. This complete divestment marks a significant shift in the shareholder structure for the Bengaluru-based healthcare technology company, removing a major institutional block from its public float.

The disclosures were filed under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, on August 7, 2026. Both filings confirm that neither BPC Genesis Fund I SPV Limited nor BPC Genesis Fund I-A SPV Limited holds any interest in Indegene Ltd post-transaction. The transactions were authorized by Mark F. Dzialga, Managing Member of the respective SPVs, acting through Brighton Park Capital Fund I GP, L.P., and Brighton Park Capital Fund I UGP, L.L.C.

Transaction Details

The sales involved only shares carrying voting rights, with no warrants, convertible securities, or encumbered shares involved. Prior to the sales, BPC Genesis Fund I SPV held 13,862,223 shares (5.757% voting capital), while BPC Genesis Fund I-A SPV held 7,190,255 shares (2.986% voting capital). Post-transaction, both entities report zero holdings across all categories.

Capital Structure Context

The total equity share capital of Indegene Ltd remained unchanged at 240,807,964 equity shares following the transactions, based on the shareholding pattern for the quarter ended March 31, 2026. The total diluted share/voting capital stands at 241,466,564 equity shares. Neither seller is part of the promoter or promoter group of the target company.

What the Numbers Show

The simultaneous complete divestment by both BPC Genesis entities indicates a full realization of their investment strategy in Indegene Ltd. With the combined stake dropping from 8.743% to zero, the Brighton Park Capital group has removed itself entirely from the company’s substantial shareholder list. The open market nature of the sales suggests a liquidity event rather than a strategic transfer or off-market deal, impacting the public float dynamics slightly but leaving the promoter group’s control unaffected.